Advancing gastrointestinal cancer diagnostics: a systematic review and meta-analysis of circulating microRNA-1246 as a non-invasive biomarker.

IF 2 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Biomarkers Pub Date : 2024-07-01 Epub Date: 2024-05-14 DOI:10.1080/1354750X.2024.2350714
Amir Hossein Aalami, Ali Shahriari, Mohammad Mazaheri, Farnoosh Aalami, Amirhossein Sahebkar
{"title":"Advancing gastrointestinal cancer diagnostics: a systematic review and meta-analysis of circulating microRNA-1246 as a non-invasive biomarker.","authors":"Amir Hossein Aalami, Ali Shahriari, Mohammad Mazaheri, Farnoosh Aalami, Amirhossein Sahebkar","doi":"10.1080/1354750X.2024.2350714","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite numerous reports on the alterations of microRNA-1246 (miR-1246) expression level in digestive system cancers, its role in gastrointestinal cancers (GICs) remains unclear. This meta-analysis aimed to assess the diagnostic potential of circulating miR-1246 in GICs.</p><p><strong>Methods: </strong>Meta-disc version 1.4 and Comprehensive Meta-Analysis (CMA) version 3.7 software were used to calculate pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), area under the curve (AUC), Q*index and summary receiver-operating characteristic (SROC). Subgroup analyses were conducted for cancer type, sample type and geographical region. Publication bias was assessed using Begg's and Egger's tests.</p><p><strong>Results: </strong>A total of 14 articles involving 18 studies and 1526 participants (972 cases and 554 controls) were included. The diagnostic accuracy of miRNA-1246 in GICs was as follows: pooled sensitivity: 0.81 (95% CI: 0.79 - 0.83), specificity: 0.74 (95% CI: 0.71 - 0.77), PLR: 3.315 (95% CI: 2.33 - 4.72), NLR: 0.221 (95% CI: 0.153 - 0.319), DOR: 16.87 (95% CI: 9.45 - 30.09), AUC: 0.891, and Q*-index: 0.807. No publication bias was found based on Begg's (<i>p</i> = 0.172) and Egger's (<i>p</i> = 0.113) tests.</p><p><strong>Conclusion: </strong>Circulating miR-1246 shows promise as a non-invasive biomarker for early detection of GICs.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"233-243"},"PeriodicalIF":2.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2024.2350714","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite numerous reports on the alterations of microRNA-1246 (miR-1246) expression level in digestive system cancers, its role in gastrointestinal cancers (GICs) remains unclear. This meta-analysis aimed to assess the diagnostic potential of circulating miR-1246 in GICs.

Methods: Meta-disc version 1.4 and Comprehensive Meta-Analysis (CMA) version 3.7 software were used to calculate pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), area under the curve (AUC), Q*index and summary receiver-operating characteristic (SROC). Subgroup analyses were conducted for cancer type, sample type and geographical region. Publication bias was assessed using Begg's and Egger's tests.

Results: A total of 14 articles involving 18 studies and 1526 participants (972 cases and 554 controls) were included. The diagnostic accuracy of miRNA-1246 in GICs was as follows: pooled sensitivity: 0.81 (95% CI: 0.79 - 0.83), specificity: 0.74 (95% CI: 0.71 - 0.77), PLR: 3.315 (95% CI: 2.33 - 4.72), NLR: 0.221 (95% CI: 0.153 - 0.319), DOR: 16.87 (95% CI: 9.45 - 30.09), AUC: 0.891, and Q*-index: 0.807. No publication bias was found based on Begg's (p = 0.172) and Egger's (p = 0.113) tests.

Conclusion: Circulating miR-1246 shows promise as a non-invasive biomarker for early detection of GICs.

推进胃肠道癌症诊断:循环 microRNA-1246 作为非侵入性生物标记物的系统回顾和荟萃分析》。
背景:尽管有许多关于消化系统癌症中microRNA-1246(miR-1246)表达水平改变的报道,但其在胃肠道癌症(GICs)中的作用仍不清楚。这项荟萃分析旨在评估循环 miR-1246 在胃肠癌中的诊断潜力:方法:使用 Meta-disc V.1.4 和 Comprehensive Meta-Analysis V.3.7 软件计算集合灵敏度、特异性、似然比、诊断几率比、AUC、Q*指数和 SROC。根据癌症类型、样本类型和地理区域进行了分组分析。采用Begg's和Egger's检验评估发表偏倚:共纳入了 14 篇文章,涉及 18 项研究和 1,526 名参与者(972 例病例和 554 例对照)。miRNA-1246 在 GIC 中的诊断准确性如下:汇总灵敏度:0.81(95% CI:0.79 - 0.83),特异性:0.74(95% CI:0.71 - 0.77),PLR:3.315(95% CI:2.33 - 4.72),NLR:0.221(95% CI:0.153 - 0.319),DOR:16.87(95% CI:9.45 - 30.09),AUC:0.891,Q*:0.891:0.891,Q*指数:0.807:0.807.根据 Begg's 检验(P = 0.172)和 Egger's 检验(P = 0.113),未发现发表偏倚:结论:循环 miR-1246 有望成为早期检测 GIC 的非侵入性生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomarkers
Biomarkers 医学-毒理学
CiteScore
5.00
自引率
3.80%
发文量
140
审稿时长
3 months
期刊介绍: The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信